Effect of Parathyroid Function After Thyroidectomy and Radioactive-Iodine Therapy for Thyroid Disease

Liu Xiao, Wenjie Zhang and Lin Li*

Department of Nuclear Medicine, China

*Corresponding author: Lin Li, Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37. Guoxue Alley, 610041 Chengdu, Sichuan province, PR. China

ARTICLE INFO

Received: November 01, 2019
Published: November 08, 2019

Citation: Liu Xiao, Wenjie Zhang, Lin Li. Effect of Parathyroid Function After Thyroidectomy and Radioactive-Iodine Therapy for Thyroid Disease. Biomed J Sci & Tech Res 22(4)-2019. BJSTR. MS.ID.003780.

Objective: Thyroidectomy and radioactive-iodine (RAI) treatment are two important methods for benign and malignant thyroid diseases. Thyroidectomy and RAI treatment may influence parathyroid gland function. This paper systematically reviewed the literatures on the effect of thyroidectomy and RAI on parathyroid gland function in patients with benign and malignant thyroid disease.

Subjective and Methods: We searched PubMed for English literautres by using terms of “thyroidectomy” or “radioactive iodine” and “hyperthyroidism” or “Graves’ disease” or “toxic multinodular goiter” or “toxic adenoma” or “differentiated thyroid carcinoma” and “parathyroid gland” or “calcium” or “parathyroid hormone” to review the effect of thyroidectomy and RAI on parathyroid gland function.

Result: Thyroidectomy may lead to hypocalcaemia and hypoparathyroidism both for benign thyroid disease and DTC. For benign thyroid disease, RAI treatment may cause increasing PTH in the short term and may induce parathyroid adenoma or hyperplasia in the long term. For DTC patients, parathyroid gland function may transiently decline after RAI treatment.

Conclusion: Thyroidectomy and RAI treatment may influence the parathyroid function in both benign and DTC patients. Thus, it is important to monitor PTH and blood calcium regularly in order to detect early abnormal parathyroid function for those patients.

Introduction

The thyroid gland is the largest endocrine gland in the human body. It secretes thyroid hormones that affect the metabolism. Hyperthyroidism including Graves’ disease (GD), toxic multinodular goiter (TMNG), toxic adenoma (TA) and differentiated thyroid cancer (DTC) are common thyroid diseases, for which thyroidectomy and radioactive iodine (RAI) treatment can be used. The parathyroid gland is an endocrine organ, which consists of 4 small glands located posteriorly to the thyroid in the middle aspect of the anterior neck and secretes parathyroid hormone (PTH), a polypeptide in response to low calcium levels detected in the blood. Low calcium can lead to circumoral or peripheral parasthesia, tetyan, carpopedal spasm, laryngospm, and ECG changes from long QT interval to VT arrest [1,2]. While high calcium can cause fatigue, polyuria, polydipsia, nephrolithiasis, peptic ulcer disease, altered mental status, gait instability [3-5], myalgia, arthralgia, abdominal pain [4], rare submandibular gland atrophy and sialolithiasis, metastatic pulmonary calcification [6,7], sometimes even inducing acute kidney injury or acute pancreatitis [8-13], or being life-threatening [14,15].

The parathyroid gland is an adjacent organ of the thyroid. Theoretically, thyroidectomy and RAI may influence parathyroid function. The impairment of parathyroid glands and the thyroid function can produce some corresponding symptoms. It is necessary to focus on the effect of RAI and thyroidectomy treatment on parathyroid function. We searched PubMed for English language studies by using terms of “surgery” or “thyroidectomy” or “radioactive iodine” and “hyperthyroidism” or “Graves’ disease” or “toxic multinodular goiter” or “toxic adenoma” or “differentiated thyroid carcinoma” and “parathyroid gland” or “calcium” or “parathyroid hormone” to review the effect of thyroidectomy and RAI on parathyroid gland function.
carcinoma” and “parathyroid gland” or “calcium” or “parathyroid hormone (PTH)” to summarize the effect of thyroidectomy and RAI on parathyroid gland function in patients with above mentioned benign and malignant thyroid diseases.

**Effect of Thyroidectomy on Parathyroid Function**

Thyroidectomy meaning partial or complete removal of thyroid tissue is among the most frequently performed surgical procedures in general surgery for thyroid disease including differentiated thyroid carcinoma (DTC) and hyperthyroidism. Postoperative hypocalcemia due to hypoparathyroidism is the most common complication of thyroidectomy, with a reported incidence of 1.6% - 50% [16-18]. It is reported that post-operative hypocalcemia is frequently occurred in the first and second post-operative days. Permanent hypoparathyroidism after total thyroidectomy is associated with an increased risk of death [19]. Hypocalcemia after thyroidectomy for benign diseases, apart from more frequent symptoms of hypocalcemia in patients with Graves’ disease, there were no differences in the overall frequency of biochemical hypocalcemia or decreasing PTH among benign and malignant thyroid diseases [20,21]. Generally thyroidectomy for hyperthyroidism rendered a patient to an euthyroid state faster than RAI [22]. After surgery for hyperthyroidism, young age, operative time, type of hospital, and parathyroid auto-transplantation were associated with early postoperative hypocalcemia [23].

Incidental parathyroidectomy with a reported incidence of 6.4% - 31.1%, was thought to be associated with postoperative hypocalcemia. Central neck dissection, total thyroidectomy, larger thyroid dimensions, extrathyroidal extension, tumor diameter more than 10mm, autoimmune thyroid disease, substernal goiter, females’ gender were found to be significant risk factors of incidental parathyroidectomy [24-29]. Operative time and the amount of bleeding were not the risk factors [30]. However, in the study by Chew C, they found incidental parathyroidectomy did not contribute to significant changes in postoperative serum calcium levels [31]. The injury of parathyroid gland may compromise their blood supply and lead to hypoparathyroidism [32,33]. Intraoperative parathyroid imaging can be used to mitigate surgical hypoparathyroidism in the intraoperative setting [34]. A meta-analysis showed low level of intraoperative PTH and presence of parathyroid gland in the pathological specimen were also risk factors of post-surgical hypoparathyroidism [35].

Another meta-analysis [36] also showed that perioperative PTH, preoperative vitamin D and postoperative changes in calcium were biochemical predictors for post-thyroidectomy hypocalcemia and clinical predictors included female, re-operation for bleeding, heavier thyroid specimens, parathyroid auto-transplantation. Parathyroid autografts not only increased the rate of postoperative hypocalcemia but may increase the chance of permanent hypoparathyroidism [37]. However, some studies revealed parathyroid auto-transplantation is a vital tool to avoid or minimize the risk for hypoparathyroidism following thyroidectomy [38,39]. The number of parathyroid glands remaining in situ was an important factor in prevention of permanent hypoparathyroidism [40]. A higher number of autotransplanted glands did not increase the chance of permanent hypoparathyroidism [39]. Thyroidectomy may cause hypocalcemia or hypoparathyroidism. Undiagnosed hypoparathyroidism can lead to multiple systemic sequelae such as chronic renal function impairment, reduced bone remodeling, increased psychiatric complaints and basal ganglia calcification [2,41]. It is important to monitor parathyroid gland function after thyroidectomy.

Parathyroid hormone assay twenty minutes after thyroidectomy is an accurate way for predicting clinically relevant hypocalcemia [42]. In the study by Filho E they found that serum intact PTH levels measured with 4 hour or on the first morning after surgery are predictors of postoperative hypocalcemia [43,44]. Some studies indicated that intact PTH level on the first day after total thyroidectomy is a very useful predictor of permanent hypoparathyroidism due to its high negative predictive value. Serum intact PTH levels above 5 pg/ml virtually exclude presence of permanent hypoparathyroidism [45,46]. Indocyanine green (ICG) angiography can predict the vascularization of the parathyroid gland and obviate the need for postoperative measurement of calcium and PTH [47]. The oral calcium and vitamin D supplements play an important role in order to avoid postoperative hypocalcemia and increase the likelihood of a safe and early discharge from the hospital [48]. Some factors associated with surgery [44] such as different anesthetic technique, site and procedure of surgery, duration of surgery, character of the patient can influence parathyroid function. A study reported that different anesthetic techniques can increase PTH levels from the reinduction to 3 minutes postinduction [49]. Some surgery of PTH excreting endocrine pancreatic neoplasm can decrease PTH and blood calcium levels [50,51]. Bariatric surgery may lead to the prevalence of secondary norm calcemic hyperparathyroidism, ranging from 17% - 70% [52,53]. The primary hyperparathyroidism patients who had parathyroid hyperplasia and osteoporosis may have higher incidence of postoperative hypocalcemia after parathyroidectomy [54].

**Effect of RAI Treatment on Parathyroid Function for Benign Thyroid Disease**

RAI treatment can be used in benign thyroid diseases including Graves’ disease, toxic multinodular goiter or toxic adenoma. The therapeutic dose of RAI for benign diseases is lower than that for DTC. Since 1975 [55], the cases of subsequent development of hyperparathyroidism after RAI treatment has been reported. Colaco [56] summarized that 40 cases of RAI treatment patients eventually developed hyperparathyroidism (including parathyroid adenoma and hyperplasia) without finding any malignant tumor. The mean age of the patients at the time of RAI treatment was 58.9 ± 12.8 years and the mean latency period was 12.9 ± 8.8 years. The latent period was long. It could be the reason why a part of the
The specific mechanism of hyperparathyroidism after RAI treatment is still under debate, but the main risk factors may be related to age and treatment dose. Triggs and Williams [69] reported a high frequency of parathyroid adenomas in newborn rats after RAI treatment within 2 days of life. In addition, S Hanthi M [70] found that the older the patients were treated with RAI, the shorter the incubation time of developing hyperparathyroidism was. The parathyroid of older patients was more sensitive to RAI, which may be related to the instability of genes, thus leading to damage of apoptosis mechanism [71]. On the contrary, the younger the age of radiation exposure, the more likely it is to develop thyroid cancer earlier [72]. In the study by Piotr Szumowski [73], they treated benign thyroid diseases with absorbed dose of 140Gy, 180Gy and 240Gy according to different disease category, and found that PTH increased most significantly in patients with absorbed dose 240Gy within 6 months after RAI treatment. However, Hamilton TE [74] unmasked that the higher dose of exposure radiation may not increase the risk of hyperparathyroidism. Fjalling M studied 125 cases of hyperparathyroidism patients after RAI treatment with a average followed-up 20 years [75]. It was found that there was no increase in the incidence of hyperparathyroidism, which may be a bias caused by relatively small number of cases.

There are few studies reported on the short-term effects of the parathyroid gland function after RAI treatment. In the study by Piotr Szumowski [73], they investigated the PTH changes in patients (including 220 cases of toxic goiter nodules, 20 cases of non-toxicity nodular goiter and 80 cases of Graves’ disease) treated with RAI. The result showed statistically significant increases in above-normal PTH serum levels in all patients. The highest rise in serum level of PTH occurred in toxic goiter nodules patients and the lowest in Graves’ disease patients. Nevertheless, the blood calcium and blood phosphorus did not change significantly. The increase of PTH after radioactive iodine treatment may be caused by the inflammatory reaction caused by radiation. While blood calcium and phosphorus were maintained normal, which can be attributed to the mildly increased PTH whose action time was short and other regulatory mechanisms of calcium homeostasis could have been involved [76]. Ross DS [77], investigated PTH changes in 17 cases of hyperthyroidism patients after RAI treatment. The results showed that after therapy, patients quickly achieved hypothyroidism, whose PTH change was the most obvious (from 29±15 to 75±29 ng/ml).

The treatment of benign thyroid diseases with RAI may cause increasing PTH with normal blood calcium in the early time, and development of adenoma and hyperplasia may occur in the long term. Three cases of hypoparathyroidism after RAI treatment has been reported [78-80]. There are case reports about patients appearing hypocalcemia after RAI treatment as well. Olsana Lazareva [81] reported 16-year-old young male patients with Graves’ disease was given 15mCi RAI for treatment. After 11 weeks, he had paralysis, muscle spasms, fatigue and discomfort. Blood admission examination revealed reduced blood calcium and vitamin D, and highly increased PTH level. After in the process of oral calcium administration, blood calcium suddenly decreased. Eventually, it was considered as vitamin D deficiency and hungry bone syndrome (HBS)-a state of rapid calcium deposition into newly synthesized osteoid, resulting in rapid, profound, and prolonged hypocalcaemia.

The literature reported on patients who developed hyperparathyroidism after RAI treatment.

| Author       | Cases | Sex | Disease               | Age (years) | Latency (years) | Dose   | Parathyroid Disease       |
|--------------|-------|-----|-----------------------|-------------|-----------------|--------|--------------------------|
| Colaco SM    | 8     | M   | Nodular goiter         | 38 - 54     | Apr - 35        | N/A    | Adenoma                  |
| Esselstyn [61]| 4     | F   | Graves’ disease        | 11-Aug      | 28-Jun          | N/A    | Adenoma/hyperplasia       |
| Kawamura [62] | 1     | M   | Graves’ disease        | 24          | 12              | 12mc   | Adenoma/hyperplasia       |
| Bondeso [63]  | 7     | F   | Graves’ disease        | 34 - 73     | 21-Mar          | N/A    | Hyperplasia/adenoma       |
| Rosen [64]    | 4     | M   | Hyperthyroidism        | 20 - 57     | 30-Sep          | N/A    | Adenoma/hyperplasia       |
| Cundiff [65]  | 1     | M   | Hyperthyroidism        | 67          | 6               | N/A    | Adenoma                  |
| Acar [66]     | 1     | M   | Nodular goiter         | 64          | 5               | N/A    | Adenoma                  |
| Netelenbos [67]| 2    | F   | Nodular goiter         | 57 - 69     | 20-Nov          | N/A    | Hyperparathyism           |
| Rasmussen [68]| 11    | M   | Hyperthyroidism        | 22 - 75     | 19-Jan          | 6 - 30mCi | Adenoma                |
Effect of RAI Treatment on Parathyroid Function For DTC Patients

DTC is a common endocrine malignancy; the yearly incidence of DTC has nearly tripled from 4.9 per 100000 in 1975 to 14.3 per in 2009. One study predicted that PTC will become the third most common cancer in women by 2019 [84,85]. It is suggested that radiation exposure is associated with the development of thyroid carcinoma, especially the thyroid radiated directly by the irradiation dose (more than 50 - 100mGy). The smaller the contact’s age the greater the risk of thyroid cancer was [72]. This could be one of the reasons of the rising incidence of thyroid cancer. Other factors may include increased sensitivity of ultrasound scan, iodine intake, and compounds with carcinogenic potential, such as a large class of xeno biotics (flame retardants, pesticides, repellents, or thermal insulators) [86]. Currently, thyroid surgery, RAI treatment and TSH inhibition therapy have become the standard treatment regimen for DTC patients. Total thyroidectomy combined with RAI treatment will improve the overall treatment efficiency and enable patients to have higher quality of life [87].

RAI treatment following thyroidectomy is suggested for many DTC patients. The purpose of RAI treatment is to remove residual thyroid and small metastatic lesions, to facilitate postoperative follow-up and recurrence monitoring. High-dose RAI therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer [88]. It is now accepted that the RAI treatment is very safe and the advantages of treating DTC with RAI outweigh the disadvantages [89]. Treatment with RAI can produce early and late complications. The common early complications include swelling and discomfort in the neck, xerostomia, dry eye, abnormalities of taste and smell, dysphagia, nausea, vomiting, bone marrow suppression [90], gonadal damage (hypospermia or temporary amenorrhea/oligomenorrhea), nasal dryness and obstruction, and nasolacrimal obstruction [91-96]. The late complications include permanent salivary gland dysfunction, leukemia and secondary malignancy, pulmonary fibrosis, fertility problems [97-102].

The parathyroid gland is an adjacent organ of the thyroid. Theoretically, RAI may influence parathyroid function. In the study by Aytekin Guven [103], 19 DTC patients after RAI therapy (therapeutic dose 100 - 150mCi) were measured PTH, blood calcium, phosphorus at the first, third, sixth, twelfth month. PTH gradually decreased between the first and sixth month, but in the normal range, and restored baseline at twelfth month. Blood calcium level was similar to this trend without significant difference. Some patients appeared hypocalcemia without any clinical symptoms. Zhi-hua Zhao et al. [104] found there were still hypoparathyroidism happened after RAI treatment and the changes of PTH and blood calcium before and after the RAI treatment were not statistically significant. Generally, PTH reduced after RAI treatment for DTC, and a small number of patients could appear hypocalcemia. The underlying mechanism of diminished parathyroid function after RAI by a non-targeted effect of ionizing radiation called a “bystander effect” on the adjacent cells (RIBE) [103,105]. Gene expression changes may lead to RIBE occurrence [106]. There was one case reported that a patient developed hyperparathyroidism after RAI treatment for DTC. A 17-year-old male patient with thyroid papillary carcinoma underwent 2 times RAI treatment (total doses 263 mCi). Two years after RAI treatment, a parathyroid adenoma was detected by a neck ultrasound examination.

The specific risk factors that influence on the parathyroid gland function after RAI treatment for DTC are still needed to be further studied. Glazebrook G [107] found that age, sex, thyroid gland excision scope, operation method, iodine doses, neck radiation exposure, relative location between thyroid and parathyroid were not relevant risk factors of low parathyroid gland function. Aytekin Guven [103] found that age, gender, iodine dose had no impact on the PTH changes both before and after RAI therapy. Currently, the effect of RAI treatment on parathyroid gland function is not very clear yet. The studies mainly focused on the changes of PTH, blood calcium and blood phosphorus at different stages before and after the treatment of RAI. The sample sizes in these studies were small and the intervals of PTH and blood calcium measurement were different among different studies. No systematic study was published focusing on long-term (over one year) changes of PTH.

Conclusion

To sum up, thyroidectomy and RAI treatment may influence the parathyroid function in GD, TMNG, TA and DTC patients. Thyroidectomy may cause hypoparathyroidism and hypocalcaemia in benign and DTC patients. For benign thyroid disease, RAI treatment may cause increasing PTH in the short term and may induce parathyroid adenoma or hyperplasia in the long term. For DTC patients, parathyroid gland function may transiently decline after RAI treatment. It is important to monitor PTH and blood calcium regularly in order to detect early abnormal parathyroid function for those patients.

Acknowledgement

None.

Conflict of Interest

No conflict of interest.
References

1. Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, et al. (2016) Presentation of Hyperparathyroidism: Etiologies and Clinical Features. J Clin Endocrinol Metab 101: 2300-2312.

2. Hicks G, George R, Sywak M (2017) Short and long-term impact of parathyroid auto-transplantation on parathyroid function after total thyroidectomy. Gland Surg 6(Suppl 1): S75-S85.

3. Reid I, Muthukrishnan R, Patel D, Mike S Crane, Murat Akyol, et al. (2016) Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a single centre’s experience. Endocr Connect 7(10): 1105-1115.

4. Al Thani H, El Matbouly M, Al Sulaiti M, Asim M, Majzoub A, et al. (2016) Management and outcomes of hyperparathyroidism: a case series from a single institution over two decades. Ther Clin Risk Manag 14: 1337-1345.

5. Ugalde I, Bello SM, Oneto S, Ciment A (2018) The forgotten electrolyte, when hypercalcemia manifest as gait instability and altered mental status. BMJ Case Rep.

6. Pattanayak P, Santhanam P, Javadi MS, Solnes LB, Rowe SP (2017) Unilateral Submandibular Gland Atrophy and Sialolithiasis Diagnosed on 99mTc-MIBI SPECT/CT in a Patient With Primary Hyperparathyroidism. Clin Nucl Med 42 (12): 939-940.

7. Bekem LC, Souza CA, Souza AJ, Dante Luiz Escussato, Bruno Hochhegger, et al. (2017) Metastatic pulmonary calcification: high-resolution computed tomography findings in 23 cases. Radiol Bras 50(4): 231-236.

8. Hanna RM, Kaldas M, Arman F, Wang M, Hammer T, et al. (2018) Hyperparathyroidism-induced acute kidney injury in a Caucasian female due to radiographically silent systemic sarcoidosis. Clin Nephrol Case Stud 6: 21-26.

9. Lee Y, Goyal K, Prasad B (2018) Acute Kidney Injury in a 31-year-old Male as a Consequence of Multiple Myeloma. Cureus 10(6): e2861.

10. Sunkara T, Caughey ME, Rawla P, Varalagadda KS, Gaduputi V (2018) Severe Acute Pancreatitis as an Index Clinical Manifestation of Parathyroid Adenoma. Cureus 10(4): e2445.

11. Otsuka Y, Kamata K, Minaga K, Takenaka M, Watanabe T, et al. (2018) Acute Pancreatitis with Disturbed Consciousness Caused by Hyperparathyroidism. Intern Med 57(21): 3075-3078.

12. Richa CG, Saad KJ, Chaaban AK, Mohamad Souheil El Rawas (2018) A rare case of hypercalcemia-induced pancreatitis in a first trimester pregnant woman. Endocrinol Diabetes Metab Case Rep.

13. Gebreselassie A, Mehari A, Dagne R, Berhane F, Kibreab A (2018) Hypercalcemic pancreatitis: a rare presentation of sarcoidosis: A case report. Medicine (Baltimore) 97(2): e9580.

14. Kawakita C, Kinomura M, Goy CJ, Chika Okita, Katsumori Katsuyama, et al. (2018) A case of fatal osteolytic hypercalcemia complicated with IgG4-related orphan disease leading to renal failure. CEN Case Rep 8(1): 20-30.

15. Marinheiro R, Parreira L, Amador P, Francisco Sardinha, Sara Goncalves, et al. (2018) Primary Ventricular Fibrillation in a Patient with Mild Hyperparathyroidism. Arq Bras Cardiol 110(4): 393-396.

16. Toniato A, Boschin IM, Piotto A Pelizzo M, Sartori P (2008) Thyroidectomy and central neck dissection for papillary thyroid carcinoma. Surgery 143(4): 171-176.

17. Puzziello A, Rosato L, Innaro N, Orlando G, Avenia N, et al. (2014) Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients. Endocrine 47(2): 537-542.
37. Sitges Serra A, Lorente Poch L, Sancho J (2018) Parathyroid auto transplantation in thyroid surgery. Langenbecks Arch Surg 403(3): 309-315.

38. Iorio O, Petrozza V, De Gori A, Bononi M, Porta N, et al. (2019) Parathyroid Auto transplantation During thyroid Surgery. Where we are? A Systematic Review on Indications and Results. J Invest Surg 32(7): 594-601.

39. Su A, Gong Y, Wu W, Li Z, Zhu J (2018) Does the number of parathyroid glands auto transplanted affect the incidence of hypoparathyroidism and recovery of parathyroid function? Surgery.

40. Lorente Poch L, Sancho JJ, Ruiz S, Sitges Serra A (2015) Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg 102(4): 359-367.

41. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, et al. (2012) Long-term follow-up of patients with hyperparathyroidism. J Clin Endocrinol Metab 97(12): 4507-4514.

42. Reddy AC, Chand G, Sabaretnam M, Mishra A, Agarwal G, et al. (2016) Prospective evaluation of intra-operative quick parathyroid hormone assay as an early predictor of post thyroidectomy hypocalcaemia. Int J Surg 34: 103-108.

43. Filho E, Machry RV, Mesquita R, Scheffel RS, Maia AL, et al. (2018) The timing of parathyroid hormone measurement defines the cut-off values to accurately predict postoperative hypocalcaemia: a prospective study. Endocrine 61(2): 224-231.

44. Mazoñas G, Wang TS (2017) The role and timing of parathyroid hormone determination after total thyroidectomy. Gland Surg 6(1): S38-S48.

45. Calvo EP, Rivera BJ, Artes CM, Serrano González J, García Pavía A, et al. (2018) Serum levels of intact parathyroid hormone on the first day after total thyroidectomy as predictor of permanent hypoparathyroidism. Endocrinol Diabetes Nutr 66(3): 195-201.

46. Marczynowska M, Snieckowska B, Żygmont A, Brazieński J, Dedecius M, et al. (2017) Postoperative hypoparathyroidism in patients after total thyroidectomy - retrospective analysis. Neuro Endocrinol Lett 38(7): 486-494.

47. Vidal FJ, Sadowski SM, Bellontai V, Guigard S, Poncet A, et al. (2018) Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery. Br J Surg 105(4): 350-357.

48. Docimo G, Toloone S, Ruggiero R, Gubitosi A, Pasquali D, et al. (2013) Total thyroidectomy without prophylactic central neck dissection combined with routine oral calcium and vitamin D supplements: is it a good option to achieve alow recurrence rate avoiding hypocalcemia? A retrospective study. Minerva Chir 68(3): 321-328.

49. Hong JC, Morris LJ, Park EJ, Ituarte PH, Lee CH, et al. (2011) Transient hypocalcaemia and recovery of parathyroid function? Surgery.

50. Matsen SL, Yeo CJ, Hruban RH, Ralph H Hruban, Michael A Choti (2005) Hypercukemia and pancreatic endocrine neoplasia with elevated PTHrP: report of two new cases and subject review. J Gastro Intest Surg 9(2): 270-279.

51. Albu A, Zirnea A, Georgescu O, Terzea D, Jinga D, et al. (2008) Malignant thyroid tumors in patients with thyrotoxicosis exposed to radioactive iodine. Acta Oncol 45(8): 1059-1061.

52. Tanaka S, Kudo A, Nagata T, Akashi M, et al. (2006) Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab 59(5): 73-77.

53. Suzuki K, Ojima M, Kodama S, Watanabe M (2006) Delayed activation of DNA damage checkpoint and radiation-induced genomic instability. Mutat Res 597(1-2): U441.

54. Colaco SM, Si M, Reiff E (2007) Hyperparathyroidism after radioactive iodine therapy. Am J Surg 194(3): 323-327.

55. Holten I, Christiansen C (1984) Unchanged parathyroid function following irradiation for malignancies of the head and neck. Cancer—Am Cancer Soc 53(4): 874-877.

56. Talma YP, Wolf GT, Esclamado R, Carroll WR, Sasser AM (1993) Ionized serum calcium levels following combined treatment for cancer of the head and neck. Laryngoscope 103(9): 1048-1051.

57. Mortensen LS, Smidt K, Jorgensen A, Nielsen JT, Laurberg P, et al. (2005) Long-term parathyroid- and c-cell function after radioiodine for benign thyroid diseases. Basic Clin Pharmacol Toxicol 97(1): 22-28.

58. Kikuchi S, Perrier ND, Ituarte P, Siperstein AE, Duh QY, et al. (2004) Latency period of thyroid neoplasia after radiation exposure. Ann Surg 239(4): 536-543.

59. Esselstyn C, Schumacher OP, Eversman J, Sheeler L, Levy WJ (1982) Hyperparathyroidism after radioactive iodine therapy for Graves’ disease. Surgery 92(5): 811-813.

60. Kawamura J, Tobisu K, Sanada S, Okada Y, Yoshida O, et al. (1983) [Hyperparathyroidism after radioactive iodine therapy for Graves’ disease: a case report]. Hinyokika Kyō ū 29(11): 1513-1519.

61. Bondseng AG, Bondseng L, Thompson NW (1998) Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence? Surgery 106(6): 1025-1027.

62. Rosen IB, Palmer JA, Rowen J, Luk SC (1984) Induction of hyperparathyroidism by radioactive iodine. Am J Surg 148(4): 441-445.

63. Cundiff JG, Portugal L, Sarne DH (2001) Parathyroid adenoma after radioactive iodine therapy for multinodular goiter. Am J Otolaryngol 22(5): 374-375.

64. Aćar T, Gomceli I, Aydin R (2003) Primary hyperparathyroidism due to giant adenoma after treatment with radioactive iodine. N Z Med J 116(1174): U441.

65. Netelenbos JG, Lips P (1981) Hyperparathyroidism after radioactive iodine therapy. Arch Intern Med 141(1): 155-1556.

66. Rasmussen T, Tavani B (2006) Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta Oncol 45(8): 1059-1061.

67. Triggs SM, Williams ED (1977) Irradiation of the thyroid as a cause of hyperparathyroidism. Lancet 1(8011): 593-594.

68. Colaco SM, Si M, Reiff E (2007) Hyperparathyroidism after radioactive iodine therapy. Am J Surg 194(3): 323-327.

69. Suzuki K, Ojima M, Kodama S, Watanabe M (2006) Delayed activation of DNA damage checkpoint and radiation-induced genomic instability. Mutat Res 597(1-2): 73-77.

70. Iglesias ML, Schmidt A, Ghuzlan AA, Lacroix L, Vatheire F, et al. (2017) Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab 61(2): 180-187.

71. Szumowski P, Abdelrazek S, Mjojak S, Bogowski F, Kociura Sawicka A, et al. (2013) Parathyroid gland function after radioiodine ([131]I) therapy for toxic and non-toxic goitre. Endokrynol Pol 64(5): 340-345.

72. Hamilton TE, Davis S, Onstad L, Kopecky KJ (2005) Hyperparathyroidism in persons exposed to iodine-131 from the Hanford Nuclear Site. J Clin Endocrinol Metab 90(12): 6545-6548.

73. Fjalling M, Dackenberg A, Hedman I, Tiselius LE (1983) An evaluation of the risk of developing hyperparathyroidism after 131I treatment for hyperthyroidism. Acta Chir Scand 149(7): 681-686.
76. Lowe H, Mc Mahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8): 3001-3005.

77. Ross DS, Nussbaum SR (1989) Reciprocal changes in parathyroid hormone and thyroid function after radioiodine treatment of hyperparathyroidism. J Clin Endocrinol Metab 68(6): 1216-1219.

78. Eipe J, Johnson SA, Kiamlo RT (1968) Hypoparathyroidism following 131-I therapy for hyperparathyroidism. Arch Intern Med 121(3): 270-272.

79. Better OS, Garty J, Braathun N (1969) Diminished functional parathyroid reserve following 131-I treatment for hyperparathyroidism. Isr J Med Sci 5: 419-422.

80. Harden RM, Harrison MT, Alexander WD (1963) Phosphate excretion and parathyroid function after radioiodine therapy and thyroidectomy. Clin Sci 25: 27-36.

81. Lazareva O, Panayiotopoulos A, Kazachkova I, Jacobson Dickman E (2014) A teenage boy with hypocalcemia after radioablation for Graves' disease. J Pediatr Endocrinol Metab 27(3-4): 379-382.

82. Witteveen JE, Van Thiell S, Romijn JA, Hamdy NA (2013) Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol 168(3): R45-R53.

83. Komarovskiy K, Raghavan S (2012) Hypocalcemia following treatment with radioiodine in a child with Graves’ disease. Thyroid 22(2): 218-222.

84. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. (2016)2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1): 1-133.

85. Aschbrook Killoy B, Schechter RB, Shih YC, Kaplan EL, Chiu BC, et al. (2013) The influence of the environment on the development of thyroid tumors: a new appraisal. Endocr Relat Cancer 21(5): T235-T254.

86. Yin X, Li Z, Zhang W, Wang X (2013) Clinical effect of total thyroidectomy combined with radioactive iodine in thyroid cancer treatment. Pak J Pharm Sci 31(4): 1252-1259.

87. Marcello MA, Malandrino P, Almeida JF, Martins MB, Cunha LL, et al. (2014) The influence of the environment on the development of thyroid tumors: a new appraisal. Endocr Relat Cancer 21(5): T235-T254.

88. Gray KD, Bannani S, Caillard C, Amant S, Ullmann TM, et al. (2018) High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer. Surgery 165(1): 37-43.

89. Tulchinsky M, Binse L, Campenni A, Ditzdaravic S, Giovanella L, et al. (2018) Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy. J Nucl Med 59(5):723-725.

90. Probst S, Abikhzer G, Chausse G, Tamilia M (2018) 1-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Mol Imaging Radionucl Ther 27(2): 84-87.

91. Fard Esfahani A, Emami Ardekan A, Falihi B, Fard Esfahani P, Beiki D, et al. (2014) Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 35(8): 808-817.

92. Savage MW, Sobel RK, Hoffman HT, Carter KD, Finkelstein MW, et al. (2015) Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following 1-31 therapy. Ophthalm Plast Reconstr Surg 31(3): e50-e52.

93. Lu L, Shan F, Li W (2016) Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer. Biomed Res Int 2016: 4376720.

94. Pashnehzar M, Takavar A, Izadyar S, Seyed Salaman Zakarias, Mahmoud Mahmoudi, et al. (2016) Gastrointestinal Side Effects of the Radioiodine Therapy for the Patients with Differentiated Thyroid Carcinoma Two Days After Prescription. World J Nucl Med 15(3): 173-178.

95. Server EA, Kirgezen T, Celebi OO, Yildiz M, Yigit O, et al. (2017) How does radioactive iodine affect the nose? Laryngoscope 127(12): 2698-2702.

96. Suat B, Deniz TE, Ozgur Y, Muhammet Y, Tefvik Fikret C (2016) The effects of radioactive iodine therapy on olfactory function. AM J Rhinol Allergy 30(6): 206-210.

97. Walgraeve D, Verhof G, Stul M, Jean Jacques Cassimana B, Cristina Mecucci, et al. (1991) Chronic myelogenous leukemia after treatment with 131I for thyroid carcinoma. Report of a case and review of the literature. Cancer Genet Cytogenet 55(2): 217-224.

98. Shimon I, Kneller O, Olchovsky D (1995) Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Clin Endocrinol (Oxf) 43(5): 651-654.

99. Laurenti L, Salutari P, Sica S, Piccirillo N, Zini G, et al. (1998) Acute myeloid leukaemia after iodine-131 treatment for thyroid disorders. Ann Hematol 76(6): 271-272.

100. Pacini F, Schumberger M, Drahle H, Smit JW, Wiersinga W, et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(4): 787-803.

101. Buyuksemit M, Paydas S, Ogul A, Emine Bağr, Melek Ergin, et al. (2018) Myeloid Neoplasia and Lymphoblastic Lymphoma with Eosinophilia After Radioactiveiodine: A Case Report. Balkan Med J 35(2): 199-202.

102. Albano D, Bertagna F, Panarotto MB, Panarotto MB, Giubbini R (2017) Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer 64(11).

103. Guven A, Salman S, Boztepe H, Yaran S, Tanakol R, et al. (2009) Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer. Ann Nucl Med 23(5): 437-441.

104. Zhao H, Li FQ, Han JK, Xiao Jun Li (2015) Effect of 131I on 'clear residual thyroid tissue' after surgery on the function of parathyroid gland in differentiated thyroid cancer. Exp Ther Med 10(6): 2079-2082.

105. Tzanella M, Thalassinos NC, Nkou A, Georgiadis G, Philokiprou D (1993) Effect of 131I treatment on the calcitonin response to calcium infusion in hyperparathyroid patients. Clin Endocrinol (Oxf) 38(1): 25-28.

106. Sokolov M, Neumann R (2018) Changes in gene expression as one of the key mechanisms involved in radiation-induced bystander effect. Biomed Rep 9: 99-111.

107. Glazerbrook GA (1987) Effect of decurie doses of radioactive iodine 131 on parathyroid function. Am J Surg 154(4): 368-373.
